ANI Raises Generics Guidance As Exclusive Prucalopride Drives Growth
US-Based Firm Says Motegrity ‘Genericization Levels Significantly Higher’ Than Reported
ANI Pharmaceuticals says it has delivered an “exceptionally strong first quarter,” with total sales reaching over $197m, amid plans to kick off a Phase IV clinical trial for Cortrophin Gel for acute gouty arthritis later this year.
